Clinical study initiated by Biodesix to further support adoption of Oncimmune’s EarlyCDT® Lung in US market

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the initiation of a study by Biodesix Inc using Oncimmune’s EarlyCDT® Lung blood test, which is marketed in the US by Biodesix as Nodify CDTTM.

Biodesix have initiated the “ALTITUDE” clinical utility study designed to evaluate the performance of Nodify LungTM (Nodify XL2TM and Nodify CDT in combination) in a randomised controlled study. The study “A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules” seeks to further demonstrate the efficacy of the Nodify XL2 and Nodify CDT tests. A secondary focus of the study will be to further understand the economic impact of the tests in guiding treatment choices and the potential impact of our tests in reducing overall healthcare costs in the US.

The ALTITUDE study objectives are to evaluate how the addition of the Nodify Lung test result impacts the clinical decision making for patients with new, incidentally identified solid lung nodules assessed as low to moderate risk of lung cancer. A total of 2,000 patients are expected to be enrolled in the study.

The trial has an adaptive study design with a blinded standard of care arm and 2:1 randomisation for open-label results for Nodify XL2. The first patients will be enrolled before the end of 2020, with Phase 1 of the study including only Nodify XL2, expected to enrol 500 patients. Phase 2 of the adaptive study design will include an open-label arm for Nodify CDT, which is aligned with Biodesix’s commercial testing algorithm.

Oncimmune’s EarlyCDT Lung blood test is marketed in the US under Biodesix’s Nodify Lung brand as Nodify CDT. The Nodify CDT test assists physicians in identifying patients with lung nodules at high risk of lung cancer and is partnered with Biodesix’s existing Nodify XL2 test, which is designed to help identify lung nodules with a very low risk of cancer. Both tests are offered in combination as the Nodify Lung Nodule Risk Assessment strategy, giving physicians the ability to order both tests from a single blood draw.

Biodesix has a direct US national sales force who sell direct into pulmonologists and corporately into national hospital systems.

Dr Adam M Hill, CEO of Oncimmune commented: “Oncimmune is committed to producing further evidence that supports both adoption and reimbursement decisions in the markets where EarlyCDT Lung is available. Part of our agreement with Biodesix in June 2019 was to continue to deliver high quality evidence in the US market with EarlyCDT Lung. The ALTITUDE study will build upon the data presented last week at the American College of Chest Physicians from the PANOPTIC study, whilst adding to the substantial evidence base already underpinning the use of our product globally.”

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn

    More articles like this

    OnTheMarket Plc

    OnTheMarket signs exclusive commercial partnership with Sprift Technologies

    OnTheMarket plc (LON:OTMP), the majority agent-owned company which operates the OnTheMarket.com property portal, has announced that it has signed an exclusive commercial partnership with Sprift Technologies Limited, the award-winning property data specialist. The partnership will enable OnTheMarket to provide

    AFC Energy

    AFC Energy: Feedback post Capital Markets Event

    AFC Energy plc (LON:AFC) hosted its maiden Capital Markets Event yesterday, giving an excellent summary of its progress in the last year and its prospects. The company is making good progress in commercialising its EV charging product alongside

    boohoo Plc

    Boohoo Group: FY21 Results

    Boohoo Group plc (LON:BOO) has announced results for the 12 months ended 28 February 2021, reporting a strong finish to the year, with performance ahead of ZC’s forecasts, driven by strong momentum in both the UK and USA

    Oncimmune acquires China rights to EarlyCDT product portfolio

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has successfully agreed to acquire the intellectual property and distribution rights for the EarlyCDT® technology in the People’s Republic of China and Hong Kong from Genostics Company Limited,

    AFC Energy

    AFC Energy hosting virtual Capital Markets event today

    AFC Energy plc (LON:AFC), a leading provider of hydrogen power generation technologies, will today host a virtual Capital Markets Event for investors and analysts at 2pm BST. To view the webcast, investors should join using the following link:

    boohoo Plc

    Boohoo Group revenue up 41% to £1.745 billion

    Boohoo Group plc (LON:BOO) has announced its final results for the year ended 28 February 2021.   2021 2020 Change   £ million £ million   Revenue 1,745.3 1,234.9 +41% Gross profit 945.2 666.3 +42% Gross margin 54.2%